High-dose recombinant interleukin-2 alone: A regimen with limited activity in the treatment of advanced renal cell carcinoma

Jeffrey S. Abrams, Anthony A. Rayner, Peter H. Wiernik, David R. Parkinson, Mario Eisenberger, Frederick R. Aronson, Rasim Gucalp, Michael B. Atkins, Michael J. Hawkins

Research output: Contribution to journalArticlepeer-review

58 Scopus citations

Fingerprint

Dive into the research topics of 'High-dose recombinant interleukin-2 alone: A regimen with limited activity in the treatment of advanced renal cell carcinoma'. Together they form a unique fingerprint.

Medicine & Life Sciences